

# Newsletter 45

| March 2019 |

## Contents

Welcome Note.	Remedica News.
Special Feature.	Health Matters.
Our Products.	Corporate Social Responsibility.
Remedica People.	A Glimpse of Cyprus.
Regulations.	Pattihis Scholarship.

## Welcome note

We are pleased to present to you issue 45 of Remedica's Newsletter.

It is hard to believe that March is already here and spring is just around the corner. Looking ahead, these past few months are already a blaze of activity and have shaped up to be the most productive period as we continue to prepare for new successes to come.

Many exciting activities have occurred over the course of this trimester. Important highlights of this issue are Remedica's New Year party at the start of the year, and the receipt of the "Gold Environment Protector Award" at the 2018 Pancyprian Environmental Awards for Organisations and Businesses award ceremony.

Remedica has also undertaken an abundance of corporate social responsibility (CSR) events such as its participation in the Limassol International Marathon and funded and organised several other events. The company participated in numerous other activities such as Career Fairs, IMH's Conference for Pharmacists and Pharmacy Owners, an interesting variety of medical conferences and a host of other events. Articles in this edition of the Newsletter are dedicated to regulations and important health matters.

We will leave you to continue reading Remedica's latest newsletter and we hope you enjoy it!

Charalambos Pattihis  
Group Chief Executive Officer (CEO)

## Special Feature.

### A clear vision behind Remedica's Success: Interview with Dr Michael Neoptolemou, Remedica Managing Director



#### 1. How crucial is it for a pharmaceutical company to keep pace with scientific research and development and to advance in this area?

It is one of the most important areas for Remedica because it is a company that constantly invests in research and development for new pharmaceuticals. These products by definition are the lungs of our company and without them we will not be able to operate in our existing markets nor penetrate into new ones. Therefore, we need to keep up with scientific advances and stay ahead of the game in the area of research and development. This is not just an important field for us but a great need, I would say.

#### 2. One of the burning topics in the Cypriot pharma sector at the moment is the implementation of the Cyprus General Healthcare System (GHS). To what extent will this be a game changer for Remedica?

Remedica is a member of one of the representative institutions dealing with the Cyprus General Healthcare System (GHS). Indeed, we belong to the Cyprus

Pharmaceutical Manufacturers' Association (CYPHAMA) that I preside over and which represents the Cyprus pharmaceutical manufacturers. Through that body, we express our opinion and our views regarding the GHS and collaborate with the Minister of Health in this regard to ensure the interests of manufacturers are preserved. With other stakeholders, we are looking specifically at how the system can be refined for patients and, as we are dealing with improving their lives, we are focusing on ensuring the affordability of medicines.

Considering that all hospitals will be autonomous, Remedica is planning important changes in the market. We are waiting to see the new distribution system, as we assume it will start directly from the manufacturers' warehouse, and we are also interested in understanding how the public tenders will be organised. We would also like to see the price fluctuation following the implementation of the GHS, as, so far, the pricing model seems uncertain. As CYPHAMA and as a pharmaceutical company, we have concerns that the reimbursement will be made by therapeutic areas and the reference product will be the less expensive of the offering. However, two products from the same category cannot necessarily be compared as there are important differences in manufacturing costs between two medicines. There will be a serious downward push for the prices. It is not the final model approved but we are wary of its impact on the industry.

In this regard, the biggest misunderstanding many governments and stakeholders have is that pharmaceutical companies are making consequent profits which is ultimately not fair to patients and other players. However, they are not considering

the fact that prices given in tenders cannot be the same as prices given in the private market for the main reason that the volumes sold between the private and the public sector are significantly different. Therefore, the price is always made following the economy of scale and it is not possible to compare the two sectors. Currently, this miscalculation is being used to establish the GHS which is why the association and Remedica are conveying the idea to the government that every single income stream has different specificities, pricing, backgrounds and reasoning and it cannot be considered in the same way in the upcoming national health system.

### 3. Today Remedica manufactures more than 300 products marketed worldwide. What are the determinants of the company's success?

The triangle of our company's success is based on providing affordable medicines of high quality, ensuring the safety of raw materials and the sustainability of our operations. We believe that the most important asset for our company is our Human Resources and this is our main concern and our main priority. As one of the most attractive organisations for employment in Cyprus and beyond, we strive to attract, develop and maintain talented people with creativity and passion for what they do.

### 4. As a people-oriented company, how important are human resources as a competitive advantage?

Human Assets are an important source of competitive advantage. Maintaining an experienced and motivated workforce plays an integral role in Remedica's productivity and its profitability. The company continually invests in its human resources and implements effective policies and practices to enrich its finely tuned and productive workforce. For Remedica, human resources are its biggest strength in terms of their experience and professional expertise. In this respect, we strive to recruit the right candidates for the right positions, providing them with adequate training and implementing programmes to develop and retain them.

### 5. How important is the role of the Cyprus Pharmaceutical Industry and by extension Remedica for the country's economy?

The role of the Cyprus Pharmaceutical Industry plays a very important part in the country's economy as pharmaceuticals are the first export product in the country, accounting for 25% of total exports of locally manufactured products in Cyprus, 2% of the gross domestic product, and an influx of millions of euros each year, employing more than 2.000 employees and it is the only sector of the economy that achieves a positive balance of exports-imports for pharmaceutical products. Remedica produces over 35% of Cypriot exports of pharmaceuticals and 7% of total exports of locally manufactured products in the country. It employs more than 650 people, of which 59% are women, while 54% of all employees have a higher education.

### 6. Talk to us about Remedica's social footprint

Remedica's contribution to the Cyprus economy is undoubtedly very important and our social footprint is in our DNA. Nowadays, the company's CSR and commitment are interwoven with its mission and extend to the areas of health, environment, human resources and the wider society. Our priority for 2019 is implementing the Remedica code of conduct, encouraging Remedica's volunteer team, strengthening relations with partners through dialogue on environmental issues, child labour, education and more.

### 7. What is your vision for Remedica?

We aspire to create a working environment that will attract, retain and develop talented people with creativity and innovation and thus deliver products that offer a competitive advantage to the company. Through its human resources, the vision is to expand Remedica's turnover by 100% over the next 5-10 years, to have a focused portfolio of products and to have systems that will help all employees to work in the most efficient and timely manner. This is the culture I want to incorporate into Remedica to achieve operational excellence in many areas of the company.

## Our Products. Refetib® (Gefetinib)

Recently, the medicinal product Refetib® 250mg Film-Coated Tablets has received its first regulatory approval. Refetib® contains the active substance Gefetinib and it is indicated for the treatment of adult patients with non-small cell lung cancer. Refetib® is available containing 250mg of the active substance in each film-coated tablet.



## Remedica People.



### Mr Michalis Vrachimis, Head of Engineering and Works Department

Mr Michalis Vrachimis completed his Bachelor's and Master's degree in Electrical and Computer Engineering at the Faculty of Engineering of the Aristotle University of Thessaloniki.

Upon his return to Cyprus in 2010, he gained employment in the global printing industry throughout which he received advanced training in countries such as Switzerland and Poland. These courses helped him to improve his skills and become acquainted with the workings of multinational industrial institutions. Subsequently, he has maintained his continuing professional development through attendance at training courses and seminars. Mr Vrachimis joined the Remedica family as a laboratory engineer in 2013. He was promoted to become Head of the Industrial Section of Engineering Department in January of 2017 and then to Head of the Engineering and Works Department in January of 2019. We wish him all the best and to continue to work with the same enthusiasm and passion.

# Regulations.

## The Cyprus General Healthcare System (GHS) and the Exportation of Medicinal Products Manufactured in Cyprus in more than 100 Countries



The value of medicinal products exported by Cypriot pharmaceutical companies exceeded €240 million in 2017, making them the country's largest export product in terms of value. Apart from exports, the contribution of the Cypriot pharmaceutical companies to the country's economy is multifaceted, providing support to a number of businesses operating in the industry and the region. "The fact that they have been supporting small and medium-sized enterprises for decades (freight forwarders, printers, graphic designers, repairmen, equipment distributors, contractors, etc.), has greatly contributed to retaining the backbone of the Cypriot economy and society, while through their CSR programmes, pharmaceutical companies support vulnerable groups of the population and allow the promotion of important social causes of non-profit organisations", says Mr Andreas Vasiliou, Head of Remedica's Drug Safety Department and Chairman of the Board of Directors of the Pancyprian Association of Manufacturers of Generic Medicinal Products (PASYPAGEF).

The Association was founded in 2017 and its members consist of Cypriot companies manufacturing generic medicines. These pharmaceutical companies, through decades of hard work and effort, have managed to put Cyprus on the world pharmaceutical map, and medicinal products manufactured in Cyprus appear in more than 100 countries, generating increased profits each year, whilst at the same time creating employment opportunities for more than 2.000 workers. However, according to Mr Vasiliou, Cypriot pharmaceutical companies are facing serious challenges that affect both their operational activities and their sustainability, such as the high electricity and water supply costs that influence their competitiveness. Another serious problem is the increased purchase price of raw materials and the high cost of distributing medicinal products to various destinations due to inadequate air and sea infrastructures linking Cyprus to other countries. The implementation of new legislations is another factor that has a negative impact on the drug industry (serialisation, GHS, etc.), raising the cost of production and distribution and causing delays in the adoption of regulatory demands due to the insufficient staffing of government services. Finally, the lack of skilled personnel in specific pharmaceutical sectors (e.g. research and development of medicines) is another challenge that the Cypriot Pharmaceutical companies are facing.



### Consideration for the GHS


Critical changes will have an effect on the pharmaceutical sector with the implementation of the GHS and industry experts warn of the risks involved. PASYPAGEF maintains that the implementation of a well-designed, universal and high-quality health system promoting equal access to all patients is imperative, and constitutes an undeniable right of every Cypriot citizen. "We must not overlook the fact that the implementation of the GHS is perceived negatively at this time due to the delay in concluding any agreement between the Health Insurance Organisation (HIO) and health providers (doctors, pharmacists, pharmaceutical companies, private hospitals, etc.)" stated Mr Vasiliou adding that "If we focus on the negotiations regarding medicinal products within the context of the GHS (with the active participation of PASYPAGEF), we will find that there is no clear conclusion as to the exact budget which will be allocated to them, due to lack of reliable financial data from the HIO. An imprecise budget for drugs could jeopardise the sustainability of local pharmaceutical industries. In this case, not only will there be shortages of

basic medicinal products in the Cypriot market, but also, based on Mercer's actuarial study conducted for the HIO, the viability and quality of the GHS will be compromised, due to the fact that low prices of generic drugs will ensure that the budget is low, but will also allow savings that can be used to introduce new health technologies into the system thus increasing the quality of services provided." Closing, Mr Vasiliou expressed the hope that the aforementioned challenges will be addressed so that the GHS will be implemented without any negative impact on Cypriot citizens granting them the opportunity to enjoy high-quality health services.

### References

Cyprus Pharmaceutical Products in Worldwide Demand. *Phileleftheros INSIDER*, 1 December 2018. 100-101.

# Remedica News.



## 1) Charalambos Pattihis, Remedica's CEO, Featured in IMH's Special InBusiness Publication for Successful Entrepreneurs (photo. 1)

IMH's InBusiness Magazine welcomed the New Year with the release, on the 6<sup>th</sup> of January 2019, of a special, collectable, double edition containing a publication dedicated to successful entrepreneurs. We are delighted to inform you that Charalambos Pattihis, Remedica's CEO, was featured in this edition, among eighty-five other entrepreneurs from all market segments, as a successful entrepreneur and a corporate leadership model. All businessmen presented in the 300-page collectable publication are executives in key positions from the Cypriot business world that have linked their name to the development of their organisation and their company, as well as to the business world in general. In this publication, Mr Pattihis discusses entrepreneurship, important moments in his career, leadership, successful business models, and much more. Some of the businessmen included in the publication, like Mr Pattihis, took over their family businesses and were acquainted early on with the business world and others are business executives who took over the leadership of major companies to strengthen and increase their success. All of them are successful leaders of top organisations.



## 2) Participation in the 20<sup>th</sup> Annual Career Exhibition (photo. 2)

Remedica participated in the 20<sup>th</sup> Annual Career Exhibition, organised by the European University of Cyprus on the 14<sup>th</sup> of March 2019 at the European University Cyprus Cultural Center. Mr Antros Yiasemi, Human Resources Manager and Mrs Christina Neophytidou, Human Resources Officer attended the Career Fair on behalf of the company. The aim of this exhibition was to inform students about trends in the labour market, internships and opportunities for full-time or part-time employment. This year, more than 100 organisations from Cyprus and abroad participated in the Exhibition, representing all sectors of the Cyprus Economy.



## 3) Remedica's New Year Party (photo. 3, 4)

The year 2019 has made a sparkling entrance for Remedica Ltd, as the company celebrated the New Year by organising a special party dedicated to its employees on the 5<sup>th</sup> of January. The evening was inaugurated by the Managing Director of the company, Dr Michael Neoptolemos, who welcomed the attendees and wished them a healthy, prosperous and creative new year. His address was dedicated to the significant successes of the company, emphasising the importance of its employees, who he described as "Remedica's biggest asset". During the evening, employees who had worked for more than twenty years in the company were honoured. Furthermore, over 100 monetary and non-monetary gifts were given to employees following a lucky draw (where contestants' names were randomly drawn out). The musical programme offered the guests a colourful voyage with the magical voices of the famous singers, Michalis Hatzigiannis and Dimitris Mpsias, who captivated the audience with their performance. Visit the following link to read the press release: <https://bit.ly/2UDWuMO>



## 4) Attendance at Medical Conferences (photo. 5)

Remedica's Local Sales team took part in medical conferences and one-day events where participants (doctors and other healthcare professionals) had the opportunity to be briefed on Remedica's new and existing products. Specifically, the team took part in: the annual congress of the Nicosia – Kyrenia Medical Association "Hippocrates", the 3<sup>rd</sup> Conference on Infections and Principles of Antimicrobial Therapy, the workshop of the Larnaca Medical Association "Apollonios", the conference of the Cyprus Society for the Study of Diabetes, and the congress titled "Updates in Dermatology".



## 5) Visits from School and University Students at Remedica's premises (photo. 6)

Between January and March, school and university students were welcomed at Remedica's premises where they had the opportunity to learn how a pharmaceutical company operates. More specifically, chemistry students of the Regional Lyceum of Apostle Lucas in Kolossi, of the Kykkos A' Lyceum in Nicosia, and of KES Collage met with members of Remedica's staff who gave presentations describing the company's activities. The students were also given a tour of Remedica's premises and had the chance to ask numerous questions regarding key aspects of Remedica's operational systems.



## 6) Participation in IMH's Conference for Pharmacists and Pharmacy Owners (photo. 7,8)

Remedica sponsored and participated in IMH's conference entitled "Conference for Pharmacists and Pharmacy Owners" held on the 23<sup>rd</sup> of January 2019 at Hilton Park Hotel, Nicosia. On behalf of the company, Dr Michael Neoptolemos, Managing Director of the company and Mr Andreas Hadjipanayis, Marketing Manager and National Sales Manager, were present among others. The aim of the conference was to provide a business forum for pharmacists and all the relevant stakeholders of the pharmaceutical sector to exchange ideas. During the conference, Dr Neoptolemos, who was among the keynote speakers, referred to the role of the pharmaceutical industry in Cyprus and the challenges it faces. The contribution of the pharmaceutical industry to Cypriot socioeconomic development is undoubtedly very important. Pharmaceutical products are the largest industrial product exported from Cyprus, producing an influx of millions of euros each year, providing work for more than 2.000 employees. In an age of digital revolution, continued investment in product and technology research is necessary in order to be in a position to face the challenges and embrace the prospects of the pharmaceutical industry.

The conference was a huge success with participants that included: pharmacists, representatives of pharmaceutical and other government departments, executives, distributors of medicines, healthcare and medical products and services, directors from private clinics and hospitals, doctors, insurance administrators and academics.

## 7) In-house Information Workshops on the Cyprus General Healthcare System - GHS (photo. 9)

Remedica organised in-house information workshops at its premises to update its staff members on the specifications of the GHS. The purpose of the meetings was to comprehensively and accurately inform its employees about the GHS provisions, its objectives and its goals. The workshops were held by Mr Andreas Vasiliou, Head of Remedica's Drug Safety Department, who answered questions from the company's staff, giving details regarding the features of the plan which will be implemented. The workshops were constructive as all the aspects of the topic were discussed, such as the implementation of an exclusive insurance health system from the 1<sup>st</sup> of June 2019, the services the system will provide, its operational mode and the way it will be funded. Remedica's mission is to alleviate suffering and improve the quality of human life by contributing to the equal access of all citizens and patients to high-quality medical and other healthcare, regardless of their social and economic status. A system promoting solidarity and justice offers Cypriot citizens the right to access high-quality medical and other healthcare and the right to choose a health care provider.



7



8



9

# Health Matters.

## World Cancer Day: 12 Recommendations to Reduce your Cancer Risk



- 1 Do not smoke. Do not use any form of tobacco.
- 2 Make your home smoke free. Support smoke-free policies in your workplace.
- 3 Take action to be a healthy body weight.
- 4 Be physically active in everyday life. Limit the time you spend sitting.
- 5 Have a healthy diet.
- 6 If you drink alcohol of any type, limit your intake. Not drinking alcohol is better for cancer prevention.
- 7 Avoid too much sun, especially for children. Use sun protection. Do not use sunbeds.
- 8 In the workplace, protect yourself against cancer-causing substances by following health and safety instructions.
- 9 Find out if you are exposed to radiation from naturally high radon levels in your home. Take action to reduce them.
- 10 For women:
  - Breastfeeding reduces cancer risk. If you can, breastfeed your baby.
  - Hormone replacement therapy (HRT) increases the risk of certain cancers. Limit use of HRT.
- 11 Ensure your children take part in vaccination programmes for:
  - Hepatitis B (for newborns).
  - Human papillomavirus (HPV) (for girls).
- 12 Take part in organised cancer screening programmes for:
  - Bowel cancer (men and women).
  - Breast cancer (women).
  - Cervical cancer (women).

Source: Published by the European Code Against Cancer in 2013 (4<sup>th</sup> edition)

# Corporate Social Responsibility: Remedica Cares



1

## 1) Participation in the Limassol International Marathon (photo. 1)

Remedica participated in the PrimeTel 5km Corporate Race of the Limassol International Marathon, which took place on the 23<sup>rd</sup> of March 2019. This Marathon is run on a flat course which follows 42.195 kilometres from the centre of the city, along the beachfront, to the ruins of the ancient city of Amathus. With a total of 126 marathon runners, Remedica's team was the 4<sup>th</sup> largest group of the marathon and out of the 228 companies that participated, our team came in 6<sup>th</sup>! In the context of the charitable purpose of the event, handmade gifts were sold at the price of 5 euros at the company's reception desk during the registration period of employees in the marathon. The amount collected was donated to the Karaiskakiou Foundation, which is run by the Bone Marrow Donor Registry, and which combines volunteering and specialised scientific support to patients with haematological malignancies both effectively and efficiently. Saliva was also collected for the Bone Marrow Donor Register before the start of the Marathon. With the arrival of the spring season accompanied by plenty of long, sunny days, participants were inspired to get out and run: the marathon was the perfect opportunity to meet with friends and keep fit while at the same time contributing to a charitable cause which was the main goal of the event.



2

## 2) Financial Support to the Association of Parents and Friends of Children with Special Needs in Limassol (photo. 2)

Remedica, in support of children with special needs, provided financial aid to the Association of Parents and Friends of Children with Special Needs in Limassol and participated in a charity dinner held on the 24<sup>th</sup> of January 2019 at the Pralina Experience cafe in Nicosia, Cyprus. The dinner was held in the memory of the late Savvas Christodoulides, the brother of the Minister of Foreign Affairs of the Republic of Cyprus, His Excellency, Dr Nikos Christodoulides who was also present at the event and was accompanied by his wife. The aim of the dinner was to raise funds for the Association in order to enable it to carry on its work and, more specifically, to be able to create a Sensory Integration Area for its Day Care Centre. The funds will also be used to support other institutions or individuals in need.



3

## 3) Remedica Awarded with a "Gold Environment Protector Award" 2018 (photo. 3)

We are delighted to inform you that Remedica was honoured with the "Gold Environment Protector Award" for 2018 within the framework of the Pancyprian Environmental Awards for Organisations and Businesses. These awards are organised by the Cyprus Center for Environmental Research and Education (CYCERE) with the support of other partners. The award was presented to Remedica during a formal official ceremony which took place at the Presidential Palace in Nicosia on the 22<sup>nd</sup> of January 2019, in the presence of the President of the Republic of Cyprus, His Excellency Mr Nicos Anastasiades. Dr Michael Neoptolemos, Managing Director of Remedica, received the award on behalf of the company. The "Gold Environment Protector Award" aims to distinguish Cypriot businesses that have taken an active role in protecting the environment in the context of their CSR programme. As a company, Remedica has long been committed to the protection of the environment and this award rewards the collective effort of the company and belongs to all those who work towards this objective.

## 4) Awareness campaign - Endomarch Cyprus 2019 (photo. 4)

Remedica provided financial support for the organisation of the Endomarch Cyprus 2019, held in March 2019. The aim of the campaign was to enlighten women in particular about the symptoms, diagnosis and the successful treatment of endometriosis, a condition that affects women during their adolescence, adulthood and maturity. The campaign's slogan was "It's Time to End the Silence". The Campaign Leader was Dr Andreas Stavroulis, Gynaecologist and Founder of the American Medical Center's Endometriosis & Fertility Center.



4

## 5) Visit of the Friends of the Neonatal Intensive Care Unit Association in Cyprus "Thermokoitida Agapis" to Remedica's Premises (photo. 5)

The Friends of the Neonatal Intensive Care Unit Association in Cyprus "Thermokoitida Agapis" visited Remedica's premises where they met with Dr Michael Neoptolemos, Managing Director. During the visit, Dr Neoptolemos spoke about the important charity work that the company carries out and made a financial contribution to help fund the association's activities. This non-governmental organisation was founded in 2011 with the main objective of raising awareness of prematurity and other causes for the hospitalisation of new-born infants in Intensive Care Units as well as providing support for the infants, their parents and the staff of the Unit in their daily endeavours. Such support, which fits in well with Remedica's overall philosophy on CSR, is also the focus of the European campaign that takes place every year on the occasion of the World Prematurity Day on the 17<sup>th</sup> of November.



5

## 6) Financial contribution to the Pattichio Senior Citizens' Centre and Participation in the Traditional Cutting of the Vasilopita (photo. 6)

Remedica provided financial support to the Pattichio Senior Citizens' Centre to support its activities and participated in the traditional cutting of the vasilopita that the centre organises annually to honour its members and friends. This year this event took place on the 29<sup>th</sup> of January 2019 and was attended on behalf of Remedica, by Mr Antros Yiasemi, Human Resources Manager who delivered the company's financial contribution to the centre's Board of Directors. Remedica is particularly sensitive to issues pertaining to the welfare of elders and will continue its efforts to further enhance and strengthen the social work of the centre.



6

# A Glimpse of Cyprus: The Neolithic Settlement of Choirokoitia.

The Neolithic settlement of Choirokoitia, occupied from the 7<sup>th</sup> to the 4<sup>th</sup> millennium B.C., is one of the most important prehistoric sites in the Eastern Mediterranean and the remains and discoveries from excavations have thrown much light on the evolution of human society in this key region. Since only part of the site has been excavated, it forms an exceptional archaeological reserve for future study.

Situated in the District of Larnaca, about 6 km from the southern coast of Cyprus, the site of the Neolithic settlement of Choirokoitia lies on the slopes of a hill partly enclosed by a loop in the Maroni River. The village covered an area of approximately 3 ha at its maximum extent. It represents the peak of the Aceramic Neolithic period of Cyprus following the first human occupation of the island by farmers from the Near East mainland. Findings have shown that the settlement consisted of circular houses built from mudbrick and stone with flat roofs, all of which were protected by a succession of walls.

A complex architectural structure providing access to the village has been uncovered at the top of the hill. The achievement of such an impressive construction, built according to a preconceived plan, indicates an important collective effort, with few known parallels in the Near East, and suggests a structured social organisation able to construct and maintain large scale works for the common good. Each house consisted of several circular buildings equipped with hearths and basins arranged around a small courtyard

where domestic activities took place. The houses belonged to both the dead, who were buried in pits beneath the rammed earthen floors, and the living. Among the finds, such as flint and bone tools, stone vessels, vegetal and animal remains, noteworthy are the anthropomorphic figurines in stone (one in clay), which point, together with funerary rituals, to the existence of elaborate beliefs.

In the prehistoric period, Cyprus played a key role in the transmission of culture from the Near East to the European world and the exceptionally well-preserved archaeological site at Choirokoitia has provided, and will continue to provide, scientific data of great importance relating to the spread of civilisation from Asia to the Mediterranean world. Both the excavated remains and the untouched part of Choirokoitia demonstrate clearly the origins of a proto-urban settlement in the Mediterranean region and beyond.

The most significant elements of the site consist mostly of the exceptionally well-preserved archaeological remains and these together with excavated artefacts, and human remains, truthfully and credibly express the value of the property as the most important Neolithic archaeological site in Cyprus. Choirokoitia makes a significant contribution to the study and understanding of the evolution of human culture in this pivotal area of the Eastern Mediterranean. Since the site was discovered, it has only been possible to carry out excavations in a small section

of the total area and conservation work has been confined to the consolidation of the construction materials. The remains, therefore, retain their authenticity in terms of form, materials, location and setting.

A management plan has been prepared, aimed at the conservation, promotion and preservation of the site's unique value for future generations, through the compilation of basic guidelines and policies for all the parties involved. The plan embraces both the physical characteristics of the site and its landscape, as well as its cultural and historical significance. Actions proposed include the improvement of visitor facilities at the site, the development of an emergency evacuation plan, landscaping of the site and the development of educational programmes and activities. Choirokoitia was given an enhanced protection status by the Committee for the Protection of Cultural Property in the Event of Armed Conflict in November 2010.

## References

United Nations Educational, Scientific and Cultural Organization (UNESCO). 2018. Choirokoitia. [ONLINE] Available at: <https://whc.unesco.org/en/list/848>. [Accessed 24 January 2019].



Πηγή: <https://whc.unesco.org/en/documents/112549>. ©Christopher Rose




Πηγή: <https://whc.unesco.org/en/documents/112551>. ©Yvon Truneau



Source: <https://whc.unesco.org/en/documents/139210>, ©Limes.Media



Source: <https://whc.unesco.org/en/documents/139206>, ©Limes.Media



Source: <https://whc.unesco.org/en/documents/139211>, ©Limes.Media

## Pattihis Family Scholarship



Remedica offers the Pattihis Family Scholarship for the academic year 2019/20 for the MSc Management degree in the Department of Management Science and Innovation at University College London (UCL).

As well as covering the programme's fees, the Scholarship includes an offer of employment with Remedica (subject to successful completion of the degree and eligibility).

Remedica is a Cypriot pharmaceutical company based in Cyprus with export activities in more than 100 countries. It specialises in the development, production and marketing of high-quality, safe and efficacious generic medicines for human use and operates in accordance with the Good Manufacturing Practice (GMP) Standards. Amongst others, it has received the Export Award no less than 8 times, the Quality Award, the Enterprise of the Year Award, and was also named by the European Business Awards as one of the top 10 export companies across Europe in 2015 and as one of the top companies in the "International Expansion" category in 2018.